Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6871 to 6885 of 8910 results

  1. Improving outcomes in colorectal cancer (CSG5)

    This guidance has been updated and replaced by NICE guideline NG151.

    Withdrawn guideline

  2. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    In development Reference number: GID-TA11008 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    In development Reference number: GID-HST10020 Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  4. Ceralasertib with durvalumab for treating advanced non-small-cell lung cancer after antiPD-L1 treatment and platinum-based chemotherapy [ID6612]

    In development Reference number: GID-TA11800 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]

    In development Reference number: GID-TA11457 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. OrganOx metra for liver transplant [ID5116]

    Discontinued Reference number: GID-TA11035

    Technology appraisal guidance
    Discontinued

  7. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTE10061 Expected publication date: TBC

    Health technology evaluations
    In development

  8. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

    Health technology evaluations
    In development

  9. Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]

    In development Reference number: GID-TA11663 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Workplace health - older employees

    Discontinued Reference number: GID-PHG59

    NICE guideline
    Discontinued

  11. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]

    In development Reference number: GID-TA10858 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [ID6247]

    In development Reference number: GID-TA11251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A [ID6312]

    In development Reference number: GID-TA11329 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Gantenerumab for treating early Alzheimer's disease [ID6142]

    In development Reference number: GID-TA11269 Expected publication date: TBC

    Technology appraisal guidance
    In development